Company profile: Intabio
1.1 - Company Overview
Company description
- Provider of real-time protein analytics and analytical solutions that transform biotherapeutic development and manufacturing by enabling early product quality characterization and delivering efficiency gains across all stages of biopharmaceutical development and manufacturing.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Intabio
Cristcot
HQ: United States
Website
- Description: Provider of drug delivery systems that combine products and specialty drug formulations, including Novel Rescue for UC Flares, a drug in Phase 3 clinical trials designed to achieve clinical remission in ulcerative colitis via mucosal healing within 4 weeks, and a patented hydrocortisone acetate suppository delivered with the Sephure applicator for consistent drug delivery and rapid bioavailability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cristcot company profile →
Qrons
HQ: United States
Website
- Description: Provider of preclinical biotech solutions developing advanced cell-based therapies and proprietary synthetic hydrogels—injectable, 3D printable polypseudorotaxane hydrogels that inhibit harmful neuronal processes and promote regeneration—and nano tellurium-based compositions to treat infectious diseases, resistant bacteria, sepsis, and neuronal diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qrons company profile →
Araris Biotech
HQ: Switzerland
Website
- Description: Provider of proprietary peptide linker technology for efficient payload attachment without antibody engineering, enabling creation of stable, homogenous, highly soluble antibody-drug conjugates (ADCs) with improved therapeutic efficacy and reduced side effects; also offers ADC development using off-the-shelf antibodies to deliver drugs to cancer cells with improved stability and solubility in a cost-effective manner.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Araris Biotech company profile →
Andrew Alliance
HQ: Switzerland
Website
- Description: Provider of robotics and software for Life Sciences, including Andrew+ pipetting robot for automated liquid handling; OneLab browser-based software to design, execute and share laboratory protocols with full traceability and error reduction; Pipette+ smart electronic pipettes; Extraction+ automated SPE system; Heater-Shaker+ for mixing and temperature control; and Shaker+ orbital shaker connected to OneLab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Andrew Alliance company profile →
PrimeraDx
HQ: United States
Website
- Description: Provider of multiplexed infectious disease assays and Scalable Target Amplification Routine technology for simultaneous quantitative measurement of multiple nucleic acid targets. Offers the ICEPlex system combining PCR and capillary electrophoresis, companion diagnostics, a C. difficile assay, ViraQuant for virus quantification, translational medicine research solutions, and pharma quality control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PrimeraDx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Intabio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Intabio
2.2 - Growth funds investing in similar companies to Intabio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Intabio
4.2 - Public trading comparable groups for Intabio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →